Onglyza, Velcade, Tyverb to win EU extensions
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline, Janssen and Bristol-Myers Squibb/AstraZeneca look set to win extensions for Tyverb (lapatinib), Velcade (bortezomib) and Onglyza (saxagliptin) respectively after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave them the green light last week. The committee's positive opinions now need to be formally approved by the European Commission.